Concepedia

Publication | Closed Access

The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection

DOI

123

Citations

0

References

1992

Year

Remko van Leeuwen, Joep M. A. Lange, Elizabeth K. Hussey, Susan T. Hall, Andrew J. Harker, Paul Jonker, Sven A. Danner
AIDS

Abstract

Overall, 3TC was well tolerated following dosing, and there were no significant changes in the safety parameters measured. Phase I/II clinical trials with 3TC are ongoing to evaluate its safety, pharmacokinetics and preliminary activity.